Fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention Group (Vitamin D capsule): The intervention group receives 50000 international unit vitamin D as pearl on a weekly basis for 12 weeks. Intervention 2: Control Group (Place
Treatment - Drugs
Intervention Group (Vitamin D capsule): The intervention group receives 50000 international unit vitamin D as pearl on a weekly basis for 12 weeks.
Control Group (Placebo): The control group will receive placebo in the same color and dose for 12 weeks.
Sponsors
Vice-chancellery of Research and Technology, Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 12 and 18 years; children with overweight and obesity based on Centers for Disease Control and Prevention of the United States; children with fatty liver based on ultrasound criteria; vitamin D deficiency under laboratory test; willingness to collaborate in the study. Exclusion criteria: Children with background diseases including known thyroid dysfunction (hypothyroidism and hyperparathyroidism), diabetes and Cushing's syndrome; chronic use of any drug such as corticosteroids, and weight reducing and weight gain drugs; history of alcoholism and hepatitis induced by other causes (hereditary diseases, viruses, etc.); and unwillingness to continue cooperation in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C-reactive protein. Timepoint: before and after intervention. Method of measurement: Laboratory test in terms of milligram per deciliter.;Fasting blood sugar. Timepoint: before and after intervention. Method of measurement: Laboratory test in terms of milligram per deciliter.;Insulin. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Aspartate Aminotransferase. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Alanine Aminotransferase. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Alkaline phosphatase. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Uric acid. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Hemoglobin. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Albumin. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Platelet. Timepoint: before and after intervention. Method of measurement: Laboratory test.;High-density lipoprotein. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Low density lipoprotein. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Cholesterol. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Triglyceride. Timepoint: before and after intervention. Method of measurement: Laboratory test.;Fatty liver. Timepoint: before and after intervention. Method of measurement: Laboratory test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mahia Hosseini
Birjand University of Medical Sciences
Outcome results
None listed